Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma

Pembrolizumab has been available for the treatment of radical resectable urothelial carcinoma (UC) when it is exacerbated after chemotherapy since December 2017 in Japan. However, the efficacy of chemotherapy for cases progressing after pembrolizumab is unclear. The present study compared the outcom...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular and clinical oncology 2021-05, Vol.14 (5), p.91-91, Article 91
Hauptverfasser:	Furubayashi, Nobuki, Hori, Yoshifumi, Morokuma, Futoshi, Tomoda, Toshihisa, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Kuroiwa, Kentaro, Tokuda, Noriaki, Nakamura, Motonobu
Format:	Artikel
Sprache:	eng
Schlagworte:	Bladder cancer Cancer Carboplatin Carcinoma Care and treatment Chemotherapy Comparative analysis Cytotoxicity Development and progression Disease control Immunotherapy Medical prognosis Metastasis Monoclonal antibodies Neutropenia Oncology Paclitaxel Patients Pemetrexed Response rates Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!